Thus, the aim of this study was to analyze the efficacy of different SGLT2 inhibitor doses compared to placebo and each other in patients with type 2 diabetes regarding HbA1c, body weight and adverse events. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.